Strep Throat Treatment Market Size, Share, and Analysis, By Drug Type (Antibiotics, Corticosteroids, NSAIDs, and Others), By Disease Type (Streptococcus A, Streptococcus B, and Others), By Route of Administration (Oral and Parenteral), By Age Group (Children and Adults), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

The strep throat treatment market is experiencing notable growth owing to the increasing demand for  patient care and treatment for this disease. The growing number of initiatives by several organizations and companies to increase awareness regarding the condition and treatment amongst the population is expected to support the market growth over the forecast period.

• In 2019, The Australian Strep A Vaccine Initiative (ASAVI) and Strep A Vaccine Global Consortium (SAVAC) took two key initiatives regarding the implementation and development of Group A Streptococcus (GAS) vaccines for the treatment of strep throat infections.

Strep Throat Treatment Market Driver

Increasing Incidence of Strep Throat amongst Population to Fuel Demand for Treatment

The rising number of patients affected by strep throat globally is leading to the growing demand for novel therapies for the condition. The growing awareness regarding the condition among the population is supporting the rising demand for the treatment in the market. In addition, the increasing focus of companies and research institutes to develop and introduce novel treatment options for the condition is another prominent factor supporting the market growth.

• In February 2023, the University of Queensland secured USD 8.0 million funding for the development of mRNA vaccine against Group A Streptococcus.

According to 2022 statistics by the European Centre for Disease Prevention and Control (ECDC), the confirmed cases of Group A Streptococcus (GAS infections) among the children in European countries ranges from 11 to over 6,600.

Strep Throat Treatment Market Restraint

Lack of Availability of Approved Treatments for Strep Throat May Hamper the Market Growth

Currently, there are no approved treatment for strep throat infection among the population which is leading to the increasing adoption of antibiotics and other off-label products for the treatment. The growing antibiotic resistance owing to its increased adoption is a major factor anticipated to hinder the adoption of these treatments among the population. Furthermore, the increased cost of these treatments make it challenging for emerging countries such as India Brazil, Mexico, and others to adopt innovative medications which further slows down the market growth.

• According to a 2023 article published by the Lancet, the antibiotic consumption for sore throat globally is estimated to exceed 37 million courses yearly, among which half of the consumption is due to the treatment for Strep A infection.

Strep Throat Treatment Market Opportunity

Soaring Antibiotic Resistance with Rising Consumption of Medications to Create Opportunities for Industry Expansion

The increasing antibiotic resistance among the population owing to the rising consumption of these medications for the treatment of strep throat presents a lucrative opportunity for manufacturers and researchers to develop and introduce vaccines for children. Along with this, the growing focus of national and international health organizations to support the development of these therapeutics is expected to create an opportunity in the market in the future.

• The World Health Organization (WHO) and its partners have published a strategic Research & Development roadmap to guide the development of the vaccine. The Strep A Vaccine Global Consortium (SAVAC) was established in 2019 with the mission to ensure the availability of safe and affordable vaccines.

Key Insights

The report covers the following key insights

• Incidence of Strep Throat, By Key Countries, 2023


• Overview of Vaccines Under Clinical Trials, By Key Companies


• New Product Launches, By Key Players


• Pipeline Analysis, By Key Players


• Key Industry Developments: Mergers, Acquisitions & Partnerships


• Impact of COVID-19 on the Market

Segmentatio

By Drug Type	By Route of Administration	By Disease Type	By Age Group	By Distribution Channel	By Geography
Antibiotics Corticosteroids NSAIDs Others	Oral Parenteral	Streptococcus A Streptococcus B Others	Children Adults	Hospital Pharmacies Drug Stores & Retail Pharmacies Online Pharmacies	North America (U.S. and Canada) Europe (U.K., Germany, France, Spain, Italy, Scandinavia, and the Rest of Europe) Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific) Latin America (Brazil, Mexico, and the Rest of Latin America) Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)

Analysis by Drug Type

By drug type, the market is segmented into antibiotics, corticosteroids, NSAIDs, and others.

The antibiotics segment accounted for a significant share of the strep throat treatment market. The increasing prescription rate for antibiotics as the first line of treatment for the condition along with rising prevalence of strep throat infection among the population are expected to boost the segment growth.

• According to 2021 data published by the U.S. Centers for Disease Control and Prevention (CDC), there is an estimated 2.8 million antibiotic prescriptions each year in the U.S. for strep throat infection.

Analysis by Route of Administration

By route of administration, the market is categorized into oral and parenteral.

The oral segment accounts for a substantial share of the global strep throat treatment market. The increased prescription of drugs of oral dosage among the population by healthcare providers for the treatment of strep throat is one of the major factors driving the growth of the segment.

• According to a 2022 article published by the CDC, the recommended dosages of antibiotics for strep throat mainly include penicillin V, amoxicillin, cephalexin, and others.

Analysis by Disease Type

Based on disease type, the market is segmented into Streptococcus A, Streptococcus B, and others.

The strep throat A segment holds a notable share in the global market. The increasing cases of strep A infection amongst the population along with the growing adoption of various treatments for the treatment of the infection are some of the key factors supporting the growth of the segment.

• According to 2020 article published by the National Center for Biotechnology Information (NCBI), the group A streptococcus accounts for nearly 5-15% of all the acute pharyngitis cases in adults and 20-30% of all the cases in children.

Analysis by Age Group

By age group, the market is segmented into children and adults.

The rising prevalence of strep throat infection among the children along with the increasing adoption of treatment for the infection are some of the factors driving the growth of the children segment.

• According to a 2023 article by NCBI, strep throat infection accounts for nearly 2-5% pediatric ambulatory visits globally.

Analysis by Distribution Channel

Based on distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

Given the easy accessibility of retail pharmacies to the general population, there exists a significant opportunity to enhance patient care through the active engagement and education using health-related content.

• A December 2023 report by Bringoz indicated that the retail pharmacies have expanded their healthcare services leading to the growing customer comfort with cost-effective care and convenience. Retail clinics has seen a significant growth of 200% from 2017 to 2022, partly driven by the heightened product usage during the pandemic.

Regional Analysis

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America had the largest share of the global strep throat treatment market in 2023. The growing incidence of strep throat in countries such as the U.S. and Canada along with the increasing diagnosis among the population in these countries are contributing to the regional market growth.

• According to 2022 statistics published by the Public Health Agency of Canada, the incidence rate of invasive group A streptococcal disease cases in Canada increased from 2.7 cases per 100,000 people in 2001 to 5.6 cases per 100,000 people in 2021.

The Europe market is projected to grow owing to the rising patient caseloads of strep throat among the population in countries such as the U.K., Germany, France, and others. The growing awareness regarding the condition is favoring the increasing treatment rate among the population for the infection.

• In July 2024, the International Group B Strep Awareness Month was observed by Group B Strep Support (GBSS), with an aim to create awareness regarding the strep throat infection among the general population.

The increasing initiatives by companies, organizations, and others to raise the awareness and diagnosis of strep throat infection among the population in countries such as India, China, Japan, and others are expected to favor the market growth in the Asia Pacific region.

Key Players Covered

The market for strep throat treatment is fragmented owing to the extensive presence of antibiotic drugs, especially the generic versions and the involvement of the various companies in the development of potential vaccines in the pipeline.

• GSK plc. (U.K.)


• Azurity Pharmaceuticals, Inc. (U.S.)


• Dr. Reddy’s Laboratories Ltd. (India)


• Bayer AG (Germany)


• Sun Pharmaceutical Industries Ltd. (India)


• AstraZeneca (U.K.)


• Pfizer Inc. (U.S.)


• Eli Lilly and Company (U.S.)

Key Industry Developments

• In March 2024, the University of Dundee, collaborated with the London School of Hygiene & Tropical Medicine and South Korea’s International Vaccine Institute and Gyeongbuk Institute for Bio-Industry with an aim to develop the first recombinant glycoconjugate vaccines for the Strep A.


• In 2022, GSK plc revealed its definitive plan to acquire Affinivax, Inc. The proposed acquisition aims to grant access to a next-generation 24-valent pneumococcal vaccine candidate in phase II development, along with the highly innovative MAPSTM technology. This move is intended to bolster the development of a robust portfolio of innovative vaccines and specialty medicines.